Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV CTL multi-epitope peptide vaccine
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
The HIV CTL multi-epitope peptide (MEP) vaccine is an investigational therapeutic and prophylactic vaccine candidate designed to elicit cytotoxic T lymphocyte (CTL) responses against human immunodeficiency virus (HIV). It consists of a mixture of four synthetic peptides, each containing one or more conserved epitopes from the env or gag proteins of HIV. These peptides are formulated with the RC529-SE adjuvant, an analogue of monophosphoryl lipid A, and may be co-administered with granulocyte-macrophage colony-stimulating factor (GM-CSF) as an additional adjuvant. The primary mechanism is to stimulate robust CD8+ T cell responses targeting multiple conserved regions of the virus, aiming to overcome viral diversity and enhance immune control. The product was developed by Wyeth Vaccines Research for use in prime-boost strategies in combination with other vaccines such as DNA-based candidates[1][2].
- Other names
- HIV CTL multi-epitope peptide vaccineHIV CTL MEP vaccine
02
Targets
MHC I (MHC class I})
Beyond the preview
Go deeper on HIV CTL multi-epitope peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV CTL multi-epitope peptide vaccine.